Cancer Family
Malignant Thoracic Neoplasm
CI-CAN-00000256Explore in graph →
2,773 active trials51 approved drugs626 evidence items
- NCIt
- C3576
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000256Explore in graph →
Clinical trials
11,496 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,526)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06632327 | Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer | active not recruiting | Phase 3 | 37 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05378763 | A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations(PINNACLE) | suspended | Phase 3 | 268 | Spectrum Pharmaceuticals, IncINDUSTRY |
| 1 |
| Sep 1, 2026 |
| clinicaltrials |
| NCT06712355 | Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer | recruiting | Phase 3 | 621 | BioNTech SEINDUSTRY | 14 | Sep 1, 2026 | clinicaltrials |
| NCT04538664 | A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions(PAPILLON) | active not recruiting | Phase 3 | 308 | Janssen Research & Development, LLCINDUSTRY | 26 | Aug 31, 2026 | clinicaltrials |
| NCT07796100 | A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer | not yet recruiting | Phase 3 | 530 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 0 | Aug 31, 2026 | clinicaltrials |
| NCT05211895 | A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC(PACIFIC-8) | active not recruiting | Phase 3 | 791 | AstraZenecaINDUSTRY | 28 | Aug 28, 2026 | clinicaltrials |
| NCT05298423 | Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)(KEYVIBE-006) | completed | Phase 3 | 610 | Merck Sharp & Dohme LLCINDUSTRY | 25 | Aug 28, 2026 | clinicaltrials |
| NCT01064466 | Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms(Drugs-SNPs) | active not recruiting | Phase 2 / Phase 3 | 600 | Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB ChairINDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT03811002 | Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC) | active not recruiting | Phase 3 | 544 | National Cancer Institute (NCI)NIH | 2 | Aug 27, 2026 | clinicaltrials |
| NCT01652469 | Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.(EMPHASIS) | completed | Phase 3 | 81 | ETOP IBCSG Partners FoundationNETWORK | 12 | Aug 26, 2026 | clinicaltrials |
| NCT04025879 | A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer | active not recruiting | Phase 3 | 461 | Bristol-Myers SquibbINDUSTRY | 22 | Aug 26, 2026 | clinicaltrials |
| NCT04656652 | Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) | active not recruiting | Phase 3 | 605 | Daiichi SankyoINDUSTRY | 26 | Aug 26, 2026 | clinicaltrials |
| NCT05722015 | A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77) | active not recruiting | Phase 3 | 377 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Aug 26, 2026 | clinicaltrials |
| NCT06212752 | A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension | active not recruiting | Phase 3 | 39 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06350097 | Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer(TROPION-Lung14) | recruiting | Phase 3 | 582 | AstraZenecaINDUSTRY | 19 | Aug 26, 2026 | clinicaltrials |
| NCT07128199 | A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection(REZILIENT4) | active not recruiting | Phase 3 | 360 | Taiho Oncology, Inc.INDUSTRY | 24 | Aug 26, 2026 | clinicaltrials |
| NCT07739186 | A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06) | not yet recruiting | Phase 2 / Phase 3 | 120 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06647953 | Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma | recruiting | Phase 3 | 110 | Children's Oncology GroupNETWORK | 2 | Aug 25, 2026 | clinicaltrials |
| NCT06765109 | Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC(ALKAZAR) | recruiting | Phase 3 | 450 | Nuvalent Inc.INDUSTRY | 29 | Aug 25, 2026 | clinicaltrials |
| NCT05899608 | Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients | recruiting | Phase 3 | 1,600 | Summit TherapeuticsINDUSTRY | 17 | Aug 24, 2026 | clinicaltrials |
| NCT07680790 | Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02) | not yet recruiting | Phase 3 | 850 | Bristol-Myers SquibbINDUSTRY | 16 | Aug 24, 2026 | clinicaltrials |
| NCT07739758 | A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer | recruiting | Phase 3 | 442 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07777822 | Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC(RASolve 308) | recruiting | Phase 3 | 430 | Revolution Medicines, Inc.INDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05317858 | Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets(LIMITLESS) | recruiting | Phase 3 | 30 | InSightecINDUSTRY | 3 | Aug 19, 2026 | clinicaltrials |
| NCT06624059 | A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)(HORIZON 2) | completed | Phase 3 | 11 | Hoffmann-La RocheINDUSTRY | 6 | Aug 19, 2026 | clinicaltrials |
| NCT07109531 | ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy | recruiting | Phase 3 | 286 | Jiangsu Aosaikang Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07499674 | Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung(VISUALIZE-2) | recruiting | Phase 3 | 132 | Vergent Bioscience, Inc.INDUSTRY | 2 | Aug 19, 2026 | clinicaltrials |
| NCT03789604 | A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer | completed | Phase 3 | 479 | CStone PharmaceuticalsINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04929041 | Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative | active not recruiting | Phase 2 / Phase 3 | 427 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
| NCT05624996 | Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer | recruiting | Phase 3 | 474 | NRG OncologyOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT06500481 | Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial | recruiting | Phase 3 | 115 | NRG OncologyOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07440290 | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06074588 | Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) | active not recruiting | Phase 3 | 556 | Merck Sharp & Dohme LLCINDUSTRY | 25 | Aug 14, 2026 | clinicaltrials |
| NCT04603807 | A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases | active not recruiting | Phase 3 | 217 | Hoffmann-La RocheINDUSTRY | 18 | Aug 13, 2026 | clinicaltrials |
| NCT04853342 | To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy(FORWARD) | recruiting | Phase 3 | 318 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05671510 | ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors(PRESERVE-003) | active not recruiting | Phase 3 | 630 | OncoC4, Inc.INDUSTRY | 12 | Aug 13, 2026 | clinicaltrials |
| NCT06416410 | JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation | recruiting | Phase 3 | 392 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06956001 | Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation | recruiting | Phase 3 | 300 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07251582 | Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer(LungTime-C02) | recruiting | Phase 3 | 186 | Hunan Province Tumor HospitalOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06801834 | Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer(EVOKE-SCLC-04) | recruiting | Phase 3 | 695 | Gilead SciencesINDUSTRY | 23 | Aug 12, 2026 | clinicaltrials |
| NCT04685135 | Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation(KRYSTAL-12) | active not recruiting | Phase 3 | 453 | Mirati Therapeutics Inc.INDUSTRY | 24 | Aug 11, 2026 | clinicaltrials |
| NCT07668752 | A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation | recruiting | Phase 3 | 300 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07718737 | Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy | not yet recruiting | Phase 2 / Phase 3 | 512 | Multitude Therapeutics Inc.INDUSTRY | 2 | Aug 10, 2026 | clinicaltrials |
| NCT07754123 | Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC | not yet recruiting | Phase 3 | 206 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 0 | Aug 10, 2026 | clinicaltrials |
| NCT02453282 | Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)(MYSTIC) | active not recruiting | Phase 3 | 1,118 | AstraZenecaINDUSTRY | 17 | Aug 6, 2026 | clinicaltrials |
| NCT03706690 | A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients(PACIFIC-5) | active not recruiting | Phase 3 | 407 | AstraZenecaINDUSTRY | 10 | Aug 6, 2026 | clinicaltrials |
| NCT03924050 | Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI | completed | Phase 3 | 440 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06203210 | A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer(IDeate-Lung02) | recruiting | Phase 3 | 540 | Daiichi SankyoINDUSTRY | 23 | Aug 6, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Sep 2, 2026source: clinicaltrials